[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336253-105":59,"doc-detail-336253-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","telangiectasias-induced-by-combination-tucatinib-and-ado-trastuzumab-emtansine-in-a-patient-with-metastatic-breast-cancer","Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer","","Background: Tucatinib, a tyrosine kinase inhibitor, is used for salvage therapy in HER2-positive breast and colorectal cancer, including expanding use with ado-trastuzumab emtansine (T-DM1). Objective/Methods: A 66-year-old woman developed widespread telangiectasias after starting combination chemotherapy with tucatinib and T-DM1 for metastatic HER2-positive invasive ductal carcinoma. Results: Lesions regressed after stopping combination therapy and reappeared on tucatinib re-initiation, improving over four months following electrocautery. Conclusions: Telangiectasias may represent a previously unreported dermatologic side effect; electrocautery was safe and effective.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/telangiectasias-induced-by-combination-tucatinib-and-ado-trastuzumab-emtansine-in-a-patient-with-metastatic-breast-cancer/336253/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/telangiectasias-induced-by-combination-tucatinib-and-ado-trastuzumab-emtansine-in-a-patient-with-metastatic-breast-cancer/336253.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What medication combination is associated with the reported telangiectasias?","Question",{"text":112,"@type":113},"The case links the onset of widespread telangiectasias to combination therapy with tucatinib and ado-trastuzumab emtansine (T-DM1).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the skin lesions respond to stopping and restarting therapy?",{"text":117,"@type":113},"Lesions regressed after cessation of the combination therapy and reappeared when tucatinib was re-initiated, with gradual improvement afterward.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment was used to improve the telangiectasias?",{"text":121,"@type":113},"Electrocautery was performed on affected regions and was described as safe and effective, with improvement over the following four months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336253,1790096527,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Breast Disease 43 (2024) 61–64 61  \nDOI 10.3233/BD-230053 IOS Press  \nCase Report  \nTelangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer  \nGabriella F. Rodrigueza , ∗ , Anuj Shaha and Andrea D. Maderalb  \naLeonard M. Miller School of Medicine, University of Miami, Miami, FL, USA  \nb Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA  \nAbstract.  \nBACKGROUND: Tucatinib is a tyrosine kinase inhibitor currently used in salvage therapy for human epidermal growth factor receptor 2 (HER2)-positive breast and colorectal cancer. The use of tucatinib alone or in combination with ado-trastuzumabemtansine (T-DM1) in the treatment of advanced HER2-positive cancers is rapidly expanding.  \nOBJECTIVE/METHODS: We report the case of a 66-year-old female who presented to the dermatology clinic with a oneyear history of widespread telangiectasias that began after initiation of combination chemotherapy with tucatinib and T-DM1 for metastatic HER2-positive invasive ductal carcinoma.  \nRESULTS: The patient’s lesions regressed upon cessation of combination therapy and reappeared in the setting of tucatinibre-initiation, with gradual improvement over the following four months following electrocautery to the affected regions. CONCLUSIONS: We postulate that telangiectasias may be a previously unreported dermatologic side effect of combination treatment with tucatinib and T-DM1 . Electrocautery is a safe and effective procedure to reduce the appearance of telangiectasiasand improve patient satisfaction during chemotherapy.  \nKeywords: Tucatinib, trastuzumab, telangiectasia, breast cancer, chemotherapy, dermatology, cutaneous  \n1. Background  \nTucatinib is a tyrosine kinase inhibitor currently used in salvage therapy for human epidermal growth factor receptor 2 (HER2)-positive breast and colorectal cancer, with a clinical range that is rapidly expanding [1– 5]. We report the case of a 66-year-old female who presented to the dermatology clinic with a one-year history of widespread telangiectasias that began after initiation of combination chemotherapy with tucatinib and adotrastuzumab emtansine (T-DM1) for HER2-positive  \n*  \nCorresponding author: Gabriella F. Rodriguez, University of Miami, Miller School of Medicine, 1600 NW 10th Ave, \\#1140, Miami, FL 33136, USA. Tel.: +1 754 422 9930; E-mail: [gabriellarodriguez@med.miami.edu. ORCID:](gabriellarodriguez@med.miami.edu. ORCID:)[ ](gabriellarodriguez@med.miami.edu. ORCID:)[https://orcid.org/0000-0002-1394-6191](https://orcid.org/0000-0002-1394-6191) .  \ninvasive ductal carcinoma. The lesions regressed upon cessation of combination therapy and reappeared in the setting of tucatinib re-initiation, with gradual improvement over the following four months. As such, we postulate that telangiectasias may be a previously unreported dermatologic side effect of combination treatment with tucatinib and T-DM1 .  \n2. Case presentation  \nThe patient is a 66-year-old female with a history of well-controlled hypertension and a family history of ovarian cancer in a paternal aunt. In 2014, she was diagnosed with a locally advanced, HER2-positive, estrogen and progesterone receptor-negative invasive  \n0888-6008 © 2024 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4 .0) .  \n62 G.F. Rodriguez et al. / Telangiectasias from tucatinib and ado-trastuzumab emtansine  \nductal carcinoma of the right breast (Stage IIIA; pT1c, pN2, M0) . Genetic testing was negative for germline mutations. Treatment included 6 cycles of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab, with an additional 6 months oftrastuzumab, which was tolerated well; bilateral mastectomy and axillary node dissection given patient preference; and radiation therapy. In 2017, the patient was diag","cbCairw5PjFCWTHn","https://ap.wps.com/l/cbCairw5PjFCWTHn","pdf",201060,"English","# Background\n# Case presentation\n## Treatment timeline\n## Dermatologic findings and follow-up\n# Discussion and conclusions","[{\"question\":\"What medication combination is associated with the reported telangiectasias?\",\"answer\":\"The case links the onset of widespread telangiectasias to combination therapy with tucatinib and ado-trastuzumab emtansine (T-DM1).\"},{\"question\":\"How did the skin lesions respond to stopping and restarting therapy?\",\"answer\":\"Lesions regressed after cessation of the combination therapy and reappeared when tucatinib was re-initiated, with gradual improvement afterward.\"},{\"question\":\"What treatment was used to improve the telangiectasias?\",\"answer\":\"Electrocautery was performed on affected regions and was described as safe and effective, with improvement over the following four months.\"}]","Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer | PDF",1790014264]